Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Multicenter, Open Label, Clinical Trial of Immune Response, Safety and Tolerability of DNA Vector pPRA-PSM With Synthetic Peptides E-PRA and E-PSM in Subjects With Advance Solid Malignancies

NCT00423254 is registered in ClinicalTrials.gov with Mannkind Corporation as lead sponsor.

NCT NCT00423254
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00423254 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Multicenter, Open Label, Clinical Trial of Immune Response, Safety and Tolerability of DNA Vector pPRA-PSM With Synthetic Peptides E-PRA and E-PSM in Subjects With Advance Solid Malignancies
Lead sponsor
Mannkind Corporation
Phase
Phase 1
Overall status
Completed
Start date
February 28, 2007
Completion date
November 30, 2009
Enrollment
12 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

anal carcinoma, biliary tract cancer, bone sarcomas, breast carcinoma, carcinoma of unknown origin, primary, cervical carcinoma, colorectal, endometrial carcinoma, esophageal carcinoma, gallbladder cancer, gastric cancer, liver cancer, melanoma, mesothelioma, neuroendocrine cancer, ovarian, pancreatic carcinoma, prostate, renal, small cell lung carcinoma, soft tissue sarcomas, testicular cancer, thyroid cancer